An updated analysis of the CameL trial has shown a significant improvement in overall survival with the addition of camrelizumab to chemotherapy in treatment-naïve Chinese patients with advanced nonsquamous non-small-cell lung cancer.
A variant of the interleukin 7 gene is associated with an increased risk of immune-related adverse events in people with cancer receiving immune checkpoint inhibitor therapy, suggests research.